Behavioral Health: Using AI to predict suicide, depression and opioid misuse before it happens
November 17, 2020 @ 3:00 pm – 4:00 pm EST
The Covid-19 pandemic isn’t the only public health crisis facing America. According to Accenture, nearly 58 million adults and 8 million youth between the ages of six and 17 in the U.S. have mental health and/or substance use disorders, yet only 43% of affected adults are receiving treatment for them. Since the start of COVID, there has been a significant spike in the use of virtual behavioral health services. While effective for continued support and care, virtual health services like telehealth, webchat, and voice therapy were not designed to catch individuals on the cusp of developing a behavioral health condition. The number of undiagnosed and rapidly deteriorating patients is surely to increase as time passes leaving our health system in yet another predicament.
Join Dr Carlo Viamonte, Medical Officer at Anthem and Dr. John Frownfelter, Chief Information Officer at Jvion and Karen Murphy, Executive Vice President and CIO at Geisinger to discuss the need for widespread adoption of clinical AI how AI-driven analysis of relevant risk factors for suicide, substance abuse or self-harm can save behavioral health providers the guesswork in predicting who is at risk and payers the ability to manage underlying and hidden risks proactively and effectively. Additionally, AIMED will be sharing the results of a recent industry survey during related to the current state and future of AI investments across payer and provider organizations.
Dr Carlo Viamonte, Medical Officer, Anthem
Dr John Frownfelter, Chief Information Officer, JVION
Karen Murphy, PhD, RN, Executive Vice President and Chief Innovation Officer, Geisinger